Hidradenitis Suppurativa Market Players:
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- AstraZeneca
- Merck & Co., Inc.
- Bayer AG
- AbbVie Inc.
- Abbott
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of hidradenitis suppurativa is assessed at USD 1.15 billion.
The global hidradenitis suppurativa market size was valued at over USD 1.07 billion in 2025 and is expected to register a CAGR of around 8.2%, exceeding USD 2.35 billion revenue by 2035.
North America hidradenitis suppurativa market is expected to capture 37% share by 2035, driven by the increasing adoption of the newest technologies to address hidradenitis suppurativa.
Key players in the market include F. Hoffmann-La Roche Ltd., Business PlanningMain Product OfferingsFinancial ExecutionMain Performance IndicatorsEli Lilly and Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc., Bayer AG, AbbVie Inc., Abbott.
